Immune checkpoint blockade (ICB) immunotherapy is a first-line treatment for selected
cancers, yet the mechanisms of its efficacy remain incompletely understood. Furthermore …

Cancer immunotherapy using anti‐programmed death‐ligand 1 (PD‐L1) antibodies has
been used in various clinical applications and achieved certain results. However, such …

Blocking the inhibitory receptor PD-1 on antitumour T lymphocytes is the main rationale
underlying the clinical successes of cancer immunotherapies with checkpoint inhibitor (CI) …

Highlights•Preclinical data indicate that PARPis exhibit immune modulating properties.•The
combination of PARPi with ICIs displays significant synergistic activity in preclinical …

Reprogramming energy production from mitochondrial respiration to glycolysis is now
considered a hallmark of cancer. When tumors grow beyond a certain size they give rise to …

Programmed death-ligand 1 (PD-L1), expressed on the surface of tumor cells, can bind to
programmed cell death-1 (PD-1) on T cells. The interaction of PD-1 and PD-L1 can inhibit T …

Genome integrity is the subject of constant insult from endogenous and exogenous sources.
In order to cope, eukaryotic cells have evolved an elaborate network of DNA repair factors …

Immune checkpoint blockade therapies targeting the PD-L1/PD-1 axis have demonstrated
clear clinical benefits. Improved understanding of the underlying regulatory mechanisms …

Simple Summary Multiple myeloma (MM), a malignant plasma cell disorder, is characterized
by abnormal DNA damage response (DDR). MM cells adapt over time via gene mutations or …

Uveal melanoma (UM) is an aggressive disease with poor response to oncological
treatment, including immunotherapy. Loss of the epigenetic modifier BRCA1-associated …